Retroviral vectors applied to gene regulation studies.
2002Methods in enzymology
Murphy TJ, Pavlath GK, Wang X, Boss V, Abbott KL +5 more
PubMedM L Ellington
2 publications 2000 – 2002
What does M L Ellington research?
M L Ellington studies the effects of cyclosporin A, a drug commonly used to suppress the immune system, specifically on inflammatory responses in vascular smooth muscle cells. They have investigated how this drug inhibits the production of COX-2, a protein known to cause inflammation when its gene is activated by growth signals. By understanding this mechanism, Ellington's research has the potential to help doctors use cyclosporin A more effectively and lead to the development of better treatments for diseases tied to inflammation in blood vessels.
Key findings
- Cyclosporin A was shown to completely prevent the activation of COX-2 gene transcription in response to certain growth signals.
- Inhibition of COX-2 production by cyclosporin A occurs at the gene transcription level, not after the COX-2 protein is produced.
- This study lays the groundwork for improved anti-inflammatory therapies that use cyclosporin A or similar drugs.
Frequently asked questions
- Does Dr. Ellington study inflammation?
- Yes, Dr. Ellington's research specifically focuses on inflammation in blood vessel cells.
- What treatments has Dr. Ellington researched?
- Dr. Ellington has researched the drug cyclosporin A and its effects on reducing inflammation.
- Is Dr. Ellington's work relevant to patients with cardiovascular issues?
- Yes, their work could help improve treatments for conditions involving inflammation in cardiovascular systems.
Publications in plain English
Cyclosporin A selectively inhibits mitogen-induced cyclooxygenase-2 gene transcription in vascular smooth muscle cells.
2000Molecular pharmacology
Robida AM, Xu K, Ellington ML, Murphy TJ
Plain English
Researchers tested whether a drug called cyclosporin A (used to suppress immune systems) could block the production of COX-2, a protein that causes inflammation in blood vessel cells. They found that cyclosporin A successfully stopped COX-2 production when cells were triggered by certain growth signals, but only by preventing the cells from reading the COX-2 gene in the first place—not by interfering with the protein after it was made. This matters because it reveals exactly how cyclosporin A reduces inflammation, which could help doctors use the drug more effectively or design better anti-inflammatory treatments.
Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.